Serum beta-2-microglobulin, a marker of lymphocyte activity, was also increased in the pSS study group versus the control group (3.39 ± 1.02 vs. 1.92 ± 0.46, p < 0.01). The gene discussed is B2M; the disease is peeling skin syndrome.